Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
AI and ATMP: Patients First
0
Zitationen
2
Autoren
2025
Jahr
Abstract
This review article explores the application of artificial intelligence (AI) within Advanced Therapy Medicinal Products (ATMP) analysis, specifically focusing on challenges related to chemistry, manufacturing, and controls (CMC) and manufacturing processes. The inherent complexity and variability in ATMPs necessitate innovative solutions for potency testing, real-time process monitoring, and stability assessment. We examine how AI tools can contribute to these areas while navigating increasingly stringent regulatory landscapes. This work acknowledges the growing importance of data protection regulations worldwide, including frameworks such as HIPAA, GDPR, PIPEDA, POPIA, and LGPD, highlighting the need for secure data handling and patient privacy considerations within ATMP development and analysis. The integration of AI also necessitates attention to explainability and transparency, potentially leveraging techniques like SHAP values and physics-informed neural networks to ensure regulatory compliance and build trust in AI-driven insights.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.292 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.143 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.539 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.776 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.452 Zit.